CI
CORT icon

CX Institutional’s Corcept Therapeutics CORT Stock Holding History

CX Institutional’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28K Buy
325
+2
+0.6% +$121 ﹤0.01% 1090
2026
Q1 		$13K Buy
+323
New +$12.1K ﹤0.01% 1218

Other funds holding CORT

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
LTAS
Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
BC
Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

CX Institutional's CORT Position: Q2 2026 in Review

CX Institutional increased its Corcept Therapeutics (CORT) stake by 0.62% in Q2 2026, buying an estimated $121 and bringing the position to 325 shares worth $28K. The position accounts for ﹤0.01% of the portfolio, ranked #1090.

CX Institutional first reported a position in CORT in Q1 2026 and has held it in 2 quarters since. 61 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • CX Institutional held 325 shares of Corcept Therapeutics worth $28K as of Q2 2026.
  • CX Institutional bought 2 Corcept Therapeutics shares in Q2 2026, an estimated $121.
  • Corcept Therapeutics made up ﹤0.01% of CX Institutional's portfolio in Q2 2026, its #1090 holding.
  • CX Institutional first reported a position in Corcept Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 61 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on CX Institutional's 13F filing for Q2 2026, filed 2 Jul 2026.